Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Menu

    Imlunestrant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves Guardant360® Cdx For Eli Lilly's Inluriyo
    FDA Approves Guardant360® Cdx For Eli Lilly's Inluriyo

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250929438398/en/FDA-Approves-Guardant360-CDx-as-Companion-Diagnostic-for-Eli-Lilly-and-Companys-Inluriyo-imlunestrant-for-Treatment-of-ESR1-mutated-Advanced-Breast-Cancer

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    FDA Approves Inluriyo for Adults Metastatic Breast Cancer
    FDA Approves Inluriyo for Adults Metastatic Breast Cancer

    26 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-approves-inluriyo-imlunestrant-for-adults-with-er-her2-esr1-mutated-advanced-or-metastatic-breast-cancer-302567490.html

    PR NEWSWIRE
    26 Sep 2025
    Share Share
    Eli Lilly`s Inluriyo Receives Approval in US
    Eli Lilly`s Inluriyo Receives Approval in US

    25 Sep 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218881

    FDA
    25 Sep 2025
    Share Share
    Lilly to Present Imlunestrant Results at Breast Cancer Symposium
    Lilly to Present Imlunestrant Results at Breast Cancer Symposium

    01 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lilly-to-present-results-from-phase-3-ember-3-study-of-imlunestrant-an-oral-serd-and-additional-results-from-its-breast-cancer-portfolio-at-the-san-antonio-breast-cancer-symposium-302294496.html

    PR NEWSWIRE
    01 Nov 2024
    Share Share